Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Department of Fundamental Sciences, Faculty of Dentistry, Bursa Uludag University, Bursa 16059, Turkey.
Int J Mol Sci. 2023 Mar 2;24(5):4846. doi: 10.3390/ijms24054846.
NOD-like receptor protein 3 (NLRP3) may contribute to the growth and propagation of breast cancer (BC). The effect of estrogen receptor-α (ER-α), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) on NLRP3 activation in BC remains unknown. Additionally, our knowledge of the effect of blocking these receptors on NLRP3 expression is limited. We used GEPIA, UALCAN, and the Human Protein Atlas for transcriptomic profiling of NLRP3 in BC. Lipopolysaccharide (LPS) and adenosine 5'-triphosphate (ATP) were used to activate NLRP3 in luminal A MCF-7 and in TNBC MDA-MB-231 and HCC1806 cells. Tamoxifen (Tx), mifepristone (mife), and trastuzumab (Tmab) were used to block ER-α, PR, and HER2, respectively, on inflammasome activation in LPS-primed MCF7 cells. The transcript level of was correlated with ER-ɑ encoding gene in luminal A (ER-α, PR) and TNBC tumors. NLRP3 protein expression was higher in untreated and LPS/ATP-treated MDA-MB-231 cells than in MCF7 cells. LPS/ATP-mediated NLRP3 activation reduced cell proliferation and recovery of wound healing in both BC cell lines. LPS/ATP treatment prevented spheroid formation in MDA-MB-231 cells but did not affect MCF7. HGF, IL-3, IL-8, M-CSF, MCP-1, and SCGF-b cytokines were secreted in both MDA-MB-231 and MCF7 cells in response to LPS/ATP treatment. Tx (ER-α inhibition) promoted NLRP3 activation and increased migration and sphere formation after LPS treatment of MCF7 cells. Tx-mediated activation of NLRP3 was associated with increased secretion of IL-8 and SCGF-b compared to LPS-only-treated MCF7 cells. In contrast, Tmab (Her2 inhibition) had a limited effect on NLRP3 activation in LPS-treated MCF7 cells. Mife (PR inhibition) opposed NLRP3 activation in LPS-primed MCF7 cells. We have found that Tx increased the expression of NLRP3 in LPS-primed MCF7. These data suggest a link between blocking ER-α and activation of NLRP3, which was associated with increased aggressiveness of the ER-α BC cells.
核苷酸结合寡聚化结构域样受体蛋白 3(NLRP3)可能有助于乳腺癌(BC)的生长和增殖。雌激素受体-α(ER-α)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)对 BC 中 NLRP3 激活的影响尚不清楚。此外,我们对阻断这些受体对 NLRP3 表达影响的认识也很有限。我们使用 GEPIA、UALCAN 和 Human Protein Atlas 进行了 BC 中 NLRP3 的转录组谱分析。脂多糖(LPS)和三磷酸腺苷(ATP)用于激活腔 A MCF-7 以及三阴性乳腺癌 MDA-MB-231 和 HCC1806 细胞中的 NLRP3。他莫昔芬(Tx)、米非司酮(mife)和曲妥珠单抗(Tmab)分别用于阻断 ER-α、PR 和 HER2,以抑制 LPS 预刺激 MCF7 细胞中的炎症小体激活。在腔 A(ER-α、PR)和三阴性乳腺癌肿瘤中,的转录水平与编码基因呈正相关。未经处理和 LPS/ATP 处理的 MDA-MB-231 细胞中的 NLRP3 蛋白表达高于 MCF7 细胞。LPS/ATP 介导的 NLRP3 激活降低了两种 BC 细胞系的细胞增殖和伤口愈合的恢复。LPS/ATP 处理可防止 MDA-MB-231 细胞形成球体,但对 MCF7 无影响。HGF、IL-3、IL-8、M-CSF、MCP-1 和 SCGF-b 细胞因子在 LPS/ATP 处理后均从 MDA-MB-231 和 MCF7 细胞中分泌。Tx(ER-α 抑制)促进了 LPS 处理 MCF7 细胞后 NLRP3 的激活,并增加了迁移和球体形成。与仅用 LPS 处理的 MCF7 细胞相比,Tx 介导的 NLRP3 激活与 IL-8 和 SCGF-b 的分泌增加有关。相比之下,Tmab(Her2 抑制)对 LPS 处理的 MCF7 细胞中 NLRP3 的激活作用有限。Mife(PR 抑制)在 LPS 预刺激的 MCF7 细胞中抑制 NLRP3 激活。我们发现 Tx 增加了 LPS 预刺激的 MCF7 中 NLRP3 的表达。这些数据表明,阻断 ER-α 与 NLRP3 的激活之间存在联系,这与 ER-α BC 细胞的侵袭性增加有关。